Photo from Dana-Farber’s Breast Oncology Center/X
Jun 25, 2024, 13:37
Sacituzumab govitecan with or without pembrolizumab in TNBC
The Dana-Farber’s Breast Oncology Center shared on X:
“Dana-Farber’s Breast Oncology Center is leading a study for metastatic triple-negative (TNBC) that is PD-L1-negative offering sacituzumab govitecan with or without pembrolizumab.
For more info call 877-338-7425 or visit here.”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023